(Translated by https://www.hiragana.jp/)
Karlin, Lionel - Resultats de la cerca - Dipòsit Digital de Documents de la UAB
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
8 p, 1.0 MB Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma / Moreau, Philippe (University Hospital Hôtel-Dieu) ; Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center) ; Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nooka, Ajay K (Winship Cancer Institute. Emory University) ; Martin, Thomas (University of California San Francisco) ; Rosinol, Laura (Hospital Clínic i Provincial de Barcelona) ; Karlin, Lionel (Centre Hospitalier Lyon Sud) ; Benboubker, Lotfi (Hôpital Bretonneau) ; Mateos, Maria-Victoria (University Hospital de Salamanca) ; Popat, Rakesh (University College London Hospitals) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Sidana, Surbhi (Stanford University of Medicine) ; Delforge, Michele (University of Leuven) ; Pei, Lixia (Janssen Research & Development) ; Trancucci, Danielle (Janssen Research & Development) ; Olyslager, Yunsi (Janssen Research & Development) ; Uhlar, Clarissa (Janssen Research & Development) ; Stephenson, Tara (Janssen Research & Development) ; Rampelbergh, Rian Van (Janssen Research & Development) ; Banerjee, Arnob (Janssen Research & Development) ; Kobos, Rachel (Janssen Research & Development) ; Usmani, Saad Z (Levine Cancer Institute-Atrium Health)
What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. [...]
2023 - 10.2217/fon-2023-0171
Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818  
2.
9 p, 603.3 KB Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study / Martin, Thomas G. (University of California San Francisco, USA) ; Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France) ; Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC) ; Garfall, Alfred (University of Pennsylvania, Philadelphia, PA) ; Mateos, M. V (Hospital Universitario de Salamanca) ; San-Miguel, Jesús F. (Clínica Universidad de Navarra) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nooka, Ajay K. (Emory University, Atlanta, GA) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Chari, Ajay (Mount Sinai School of Medicine, New York, USA) ; Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France) ; Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ; Bahlis, Nizar (University of Calgary, Canada) ; Popat, Rakesh (University College London) ; Besemer, Britta (University of Tuebingen, Tuebingen, Germany) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium) ; Trancucci, Danielle (Janssen Research & Development, Raritan, NJ) ; Pei, Lixia (Janssen Research & Development, Raritan, NJ) ; Kobos, Rachel (Janssen Research & Development, Raritan, NJ) ; Fastenau, John (Janssen Research & Development, Raritan, NJ) ; Gries, Katharine S. (Janssen Research & Development, Raritan, NJ) ; van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. [...]
2023 - 10.1016/j.clml.2023.11.001
Clinical Lymphoma, Myeloma & Leukemia, 2023  
3.
4 p, 756.5 KB Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS / Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ; Haenel, M. (Klinikum Chemnitz, Germany) ; Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ; Ailawadhi, Sikander (Mayo Clinic Florida, USA) ; Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ; de la Rubia Comos, Javier (Catholic University of Valencia) ; Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ; Mateos, M. V (Hospital Universitario de Salamanca) ; Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ; Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ; Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ; Terebelo, Howard (Providence Cancer Center, Southfield, USA) ; Yang, Shiyi (Janssen Research & Development. LLC, USA) ; Wang, Jianping (Janssen Research & Development. LLC, USA) ; Nnane, Ivo (Janssen Research & Development. LLC, USA) ; Qi, Ming (Janssen Research & Development. LLC, USA) ; Kosh, Michele (Janssen Research & Development. LLC, USA) ; Delioukina, Maria (Janssen Research & Development. LLC, USA) ; Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)  

Vegeu també: autors amb noms similars
1 Karlin, L
1 Karlin, L.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.